|Dr. George F. Tidmarsh M.D., Ph.D.||Chief Exec. Officer, Pres, Sec. and Director||826.15k||N/A||57|
|Mr. Dennis M. Mulroy||Chief Financial Officer||467.98k||N/A||62|
|Ms. Jennifer A. Carver MBA||Chief Operating Officer||482.38k||N/A||63|
|Dr. Lakhmir S. Chawla M.D.||Chief Medical Officer||584.44k||N/A||46|
|Mr. James M. Rolke||Chief Scientific Officer||N/A||N/A||48|
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It engages in developing LJPC-501, a formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension; and LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. The company is also developing LJPC-30S, which is the gentamicin derivative program for the potential treatment of serious bacterial infections and rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.
La Jolla Pharmaceutical Company’s ISS Governance QualityScore as of May 1, 2017 is 9. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 3; Compensation: 10.